Analysts expect that Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will post earnings of ($0.49) per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Adamas Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.45). Adamas Pharmaceuticals posted earnings per share of ($0.59) during the same quarter last year, which would indicate a positive year-over-year growth rate of 16.9%. The company is scheduled to report its next quarterly earnings report on Thursday, May 6th.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year earnings of ($1.57) per share for the current financial year, with EPS estimates ranging from ($1.75) to ($1.22). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.80) per share, with EPS estimates ranging from ($1.20) to ($0.27). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Monday, February 22nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.11). The company had revenue of $21.01 million during the quarter, compared to analyst estimates of $20.80 million.
In other Adamas Pharmaceuticals news, Director Spyridon Papapetropoulos purchased 5,975 shares of the company’s stock in a transaction that occurred on Thursday, March 11th. The shares were acquired at an average price of $5.06 per share, with a total value of $30,233.50. Following the transaction, the director now owns 15,975 shares in the company, valued at $80,833.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Vijay Shreedhar sold 4,514 shares of the firm’s stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $6.39, for a total transaction of $28,844.46. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,438 shares of company stock valued at $83,797. Company insiders own 19.70% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in Adamas Pharmaceuticals by 9.1% in the 4th quarter. Renaissance Technologies LLC now owns 898,584 shares of the specialty pharmaceutical company’s stock valued at $3,891,000 after acquiring an additional 74,580 shares in the last quarter. BlackRock Inc. lifted its position in Adamas Pharmaceuticals by 0.8% in the 4th quarter. BlackRock Inc. now owns 534,913 shares of the specialty pharmaceutical company’s stock valued at $2,316,000 after acquiring an additional 3,994 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Adamas Pharmaceuticals during the 3rd quarter worth approximately $102,000. Squarepoint Ops LLC lifted its position in shares of Adamas Pharmaceuticals by 721.4% during the 3rd quarter. Squarepoint Ops LLC now owns 82,363 shares of the specialty pharmaceutical company’s stock worth $339,000 after buying an additional 72,336 shares in the last quarter. Finally, Silverarc Capital Management LLC purchased a new stake in shares of Adamas Pharmaceuticals during the 4th quarter worth approximately $1,909,000. 44.23% of the stock is currently owned by institutional investors and hedge funds.
Shares of ADMS stock traded up $0.28 during trading on Wednesday, hitting $5.37. The company had a trading volume of 7,303 shares, compared to its average volume of 693,008. The firm has a market capitalization of $164.15 million, a P/E ratio of -2.30 and a beta of 2.96. The stock’s 50-day moving average price is $5.01 and its 200 day moving average price is $4.74. Adamas Pharmaceuticals has a one year low of $2.43 and a one year high of $9.15.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.
Further Reading: What is a blue-chip stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.